Immunic, Inc. SEC filings IMUX

Immunic, Inc. has 832 filings in SEC EDGAR's recent list, going back to Feb 18, 2004. Its latest annual report, Form 10-K, was filed on Feb 26, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.

Immunic, Inc. SEC filings
Form Description Filed Period
S-8 Employee stock plan registration Oct 1, 2026 —
S-8 Employee stock plan registration Aug 12, 2026 —
S-3/A Filing Apr 30, 2026 —
S-8 Employee stock plan registration Apr 9, 2026 —
S-3 Shelf registration Apr 2, 2026 —
S-8 Employee stock plan registration Aug 27, 2025 —
424B5 Prospectus supplement May 30, 2025 —
424B5 Prospectus supplement May 28, 2025 —
424B5 Prospectus supplement Apr 9, 2025 —
S-8 Employee stock plan registration Jul 2, 2024 —
424B5 Prospectus supplement Jun 10, 2024 —
S-3/A Pre-effective amendment no. 1 to form s-3 May 24, 2024 —
424B3 Prospectus Apr 30, 2024 —
S-3/A Filing Mar 1, 2024 —
S-3 Shelf registration Feb 13, 2024 —
S-3 Shelf registration Nov 22, 2023 —
S-8 Employee stock plan registration Aug 21, 2023 —
424B3 Prospectus Dec 20, 2022 —
S-3 Shelf registration Dec 9, 2022 —
424B5 Prospectus supplement May 2, 2022 —
S-8 Employee stock plan registration Jul 28, 2021 —
424B5 Prospectus supplement Jul 16, 2021 —
424B5 Prospectus supplement Jul 14, 2021 —
S-3 Shelf registration Apr 16, 2021 —
424B5 Prospectus supplement Dec 29, 2020 —
S-3 Shelf registration Nov 13, 2020 —
424B5 Prospectus supplement Nov 12, 2020 —
424B5 Prospectus supplement Aug 5, 2020 —
424B5 Prospectus supplement Aug 4, 2020 —
424B5 Prospectus supplement Aug 3, 2020 —
424B5 Prospectus supplement Jun 11, 2020 —
424B5 Prospectus supplement Jun 10, 2020 —
424B5 Prospectus supplement Apr 27, 2020 —
424B5 Prospectus supplement Mar 23, 2020 —
S-8 Employee stock plan registration Sep 20, 2019 —
424B5 Prospectus supplement Jul 17, 2019 —
424B3 Prospectus Feb 19, 2019 —
S-4/A Filing Feb 14, 2019 —
S-4 Registration for a merger or exchange Feb 4, 2019 —
S-3/A Filing Jun 8, 2018 —
S-8 Employee stock plan registration May 25, 2018 —
S-3 Shelf registration May 25, 2018 —
S-8 Employee stock plan registration Feb 6, 2018 —
S-8 Employee stock plan registration May 26, 2017 —
424B5 Prospectus supplement Mar 23, 2017 —
424B5 Prospectus supplement Mar 21, 2017 —
S-8 Employee stock plan registration May 13, 2016 —
424B5 Prospectus supplement Oct 23, 2015 —
424B5 Prospectus supplement Oct 22, 2015 —
FWP Free writing prospectus Sep 28, 2015 —
S-8 Employee stock plan registration Jun 2, 2015 —
S-3 Shelf registration May 12, 2015 —
424B4 Prospectus Oct 3, 2014 —
FWP Free writing prospectus Oct 3, 2014 —
S-1/A Amended registration statement Sep 30, 2014 —
S-1 Registration statement Sep 22, 2014 —
S-8 Employee stock plan registration Jun 6, 2014 —
424B4 Prospectus Apr 17, 2014 —
FWP Free writing prospectus Apr 16, 2014 —
S-1/A Amended registration statement Apr 9, 2014 —
FWP Free writing prospectus Apr 9, 2014 —
S-1/A Amended registration statement Apr 7, 2014 —
S-1/A Amended registration statement Apr 3, 2014 —
S-1/A Amended registration statement Mar 11, 2014 —
FWP Free writing prospectus Nov 20, 2013 —
S-1/A Amended registration statement Nov 15, 2013 —
S-1/A Amended registration statement Nov 6, 2013 —
S-1/A Amended registration statement Oct 30, 2013 —
S-1 Registration statement Oct 11, 2013 —

Showing 69 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
IMUX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
New York, United States
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1280776
Former names
VITAL THERAPIES INC (until Apr 10, 2019)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.